Core Viewpoint - MapLight Therapeutics, a biotech company focused on therapies for neuropsychiatric and central nervous system diseases, has filed for an initial public offering (IPO) to raise up to $100 million [1] Company Overview - MapLight Therapeutics is headquartered in Redwood City, California, and was established in 2018 [1] - The company plans to list on the NASDAQ under the ticker symbol MPLT [1] Drug Development - The core candidate drug, ML-007C-MA, is a fixed-dose combination formulation designed for the treatment of schizophrenia and Alzheimer's disease psychosis (ADP) [1] - The company is conducting two Phase 2 clinical trials for ML-007C-MA: one for schizophrenia with topline data expected in the second half of 2026, and another for Alzheimer's disease psychosis with topline data expected in the second half of 2027 [1] IPO Details - The company submitted a confidential IPO application on March 8, 2024 [1] - The joint book-running managers for the offering include Morgan Stanley, Jefferies, Leerink Partners, and Stifel [1] - The company has not yet disclosed the pricing terms for the offering [1]